RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-R...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., December 15, 2020, /PRNewswire-AsiaNet/-- RedHill Biopharma Ltd. [https://www.redhillbio.com/RedHill/] (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study within which opaganib, a nove...
Authors: LATEST ASIANET NEWS RELEASES